{"id":"NCT01390844","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Safety and Efficacy of Boceprevir in Asia Pacific Participants With Chronic Hepatitis C Genotype 1 (P07063)","officialTitle":"Safety and Efficacy of Boceprevir in Combination With Peginterferon Plus Ribavirin for Treatment of Asia Pacific Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Pegylated Interferon Plus Ribavirin","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-10-21","primaryCompletion":"2015-06-19","completion":"2015-06-19","firstPosted":"2011-07-11","resultsPosted":"2016-06-28","lastUpdate":"2018-09-11"},"enrollment":282,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C, Chronic"],"interventions":[{"type":"DRUG","name":"Boceprevir (BOC)","otherNames":["SCH 503034","Victrelis"]},{"type":"DRUG","name":"Placebo to boceprevir","otherNames":[]},{"type":"DRUG","name":"Peginterferon alfa-2b (PEG)","otherNames":["PegIntron","SCH 054031","Redipen"]},{"type":"DRUG","name":"Ribavirin (RBV)","otherNames":["Rebetol","SCH 018908"]},{"type":"DRUG","name":"Cross-Over Boceprevir Treatment","otherNames":["SCH 503034","Victrelis"]}],"arms":[{"label":"Boceprevir","type":"EXPERIMENTAL"},{"label":"Control","type":"ACTIVE_COMPARATOR"}],"summary":"This study will assess the efficacy of boceprevir (BOC) in combination with PegIntron (pegylated interferon alfa-2b) (PEG) and ribavirin (RBV) in response guided therapy compared to the efficacy of standard-of-care therapy alone in adult subjects with chronic hepatitis C (CHC) genotype 1 who failed prior treatment with pegylated interferon and RBV in the Asia Pacific population. The primary hypothesis is that the proportion of participants achieving sustained virologic response in the experimental therapy regimen (BOC/PEG+RBV) is superior to that in the control arm (Placebo/PEG+RBV), in the Full Analysis Set (FAS) population.","primaryOutcome":{"measure":"Percentage of Participants in Korea and Taiwan With Sustained Virologic Response (SVR) at Follow-Up Week 24 - Full Analysis Set (FAS) Population","timeFrame":"Follow-up Week 24","effectByArm":[{"arm":"Boceprevir - Korea+Taiwan","deltaMin":60.9,"sd":null},{"arm":"Control - Korea+Taiwan","deltaMin":26.15,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":10},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":16,"n":133},"commonTop":["Anaemia","Pyrexia","Pruritus","Alopecia","Dizziness"]}}